Real-world outcomes of interleukin-17 inhibitors in familial Mediterranean fever-associated inflammatory conditions: a retrospective study
Immunotherapy, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1080/1750743x.2026.2755170
- Dergi Adı: Immunotherapy
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE, Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: autoinflammatory diseases, Familial Mediterranean fever, immune-mediated inflammatory diseases, interleukin-17 inhibitors, ixekizumab, secukinumab, spondyloarthritis
- Gazi Üniversitesi Adresli: Evet
Özet
Aims: To evaluate the real-world effects of interleukin-17 (IL-17) inhibitors on familial Mediterranean fever (FMF) activity and associated immune-mediated inflammatory diseases (IMIDs). Patients and methods: We retrospectively evaluated 16 patients with FMF who received IL-17 inhibitors primarily for coexisting IMIDs between 2015 and 2026. FMF attack frequency, C-reactive protein (CRP) levels, spondyloarthritis activity indices, treatment duration, discontinuation reasons, and adverse events were assessed. Results: Among 13 patients with available FMF activity data, attack frequency remained unchanged in 9 (69%), increased in 3 (23%), and decreased in 1 (8%). CRP levels did not significantly improve. In six patients with FMF-spondyloarthritis overlap and available 3-month data, BASDAI and ASDAS-CRP showed improvement. IL-17 inhibitor therapy was discontinued in 14 patients, most commonly because of inadequate control of the associated IMID. Conclusions: IL-17 inhibition did not consistently improve core FMF activity in this highly selected, treatment-refractory cohort, although some domain-specific benefit was observed in spondyloarthritis. These findings are hypothesis-generating and require confirmation in prospective controlled studies.